Angioplasty and Coronary Stenting

Percutaneous coronary intervention (PCI) — encompassing balloon angioplasty and coronary stenting — is among the most frequently performed cardiac procedures in the United States, with more than 600,000 PCI procedures performed annually according to the American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR). This page covers the mechanical basis of the procedure, the device categories used, the clinical situations that prompt its use, and the decision framework that separates PCI from alternative strategies. Understanding these boundaries is foundational to the broader overview of cardiology interventions and to navigating the regulatory context for cardiology that governs how these procedures are approved, performed, and monitored.

Definition and Scope

Percutaneous coronary intervention is a catheter-based technique for opening narrowed or blocked coronary arteries without open-chest surgery. The term "angioplasty" refers specifically to the mechanical widening of a vessel lumen, while "stenting" describes the implantation of a metal or polymer scaffold that holds the artery open after dilation. In clinical practice, the two are almost always combined; standalone balloon angioplasty without stent placement is now reserved for specific anatomical or clinical situations, such as small-caliber vessels or stent-inaccessible lesions.

The U.S. Food and Drug Administration (FDA) regulates coronary stents as Class III medical devices under 21 CFR Part 870, requiring premarket approval (PMA) before clinical use (FDA Medical Device Regulation, 21 CFR Part 870). Two broad device categories are FDA-approved for coronary use:

  1. Bare-metal stents (BMS) — stainless steel or cobalt-chromium mesh frames with no drug coating; lower cost, shorter required dual antiplatelet therapy (DAPT) duration, but higher restenosis rates compared to drug-eluting stents.
  2. Drug-eluting stents (DES) — polymer-coated stents that elute antiproliferative agents (sirolimus, everolimus, zotarolimus, or paclitaxel) to suppress neointimal hyperplasia; first-generation DES required 12 months of DAPT, while contemporary second- and third-generation DES may permit shorter durations in lower-bleeding-risk patients per ACC/AHA guideline updates.

A third category — bioresorbable vascular scaffolds (BVS) — was granted FDA approval in 2016 but was subsequently withdrawn from the U.S. market by its manufacturer in 2017 following data showing higher thrombosis rates compared to metallic DES. The classification boundaries between these device types carry direct implications for post-procedure antiplatelet management.

How It Works

PCI follows a structured sequence of steps, each associated with specific equipment and defined risk checkpoints:

  1. Vascular access — A sheath is introduced into the radial or femoral artery. The ACC/AHA PCI Guidelines (2022 update) recommend radial access as the default approach in most patients due to reduced access-site bleeding compared to femoral access.
  2. Guide catheter placement — A guide catheter is advanced through the aorta to the coronary ostium under fluoroscopic visualization.
  3. Coronary angiography — Contrast is injected to define the lesion location, length, and severity. Fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR) pressure wire measurements may be added to assess hemodynamic significance of intermediate lesions (typically defined as 40–70% diameter stenosis on angiography).
  4. Guidewire crossing — A 0.014-inch coronary guidewire is advanced across the lesion into the distal vessel.
  5. Balloon pre-dilation — An angioplasty balloon is inflated at the lesion site, compressing plaque and stretching the vessel wall. Balloon pressures typically range from 6 to 20 atmospheres depending on lesion hardness.
  6. Stent deployment — The stent, pre-mounted on a balloon catheter, is positioned at the lesion and expanded. Intravascular imaging — optical coherence tomography (OCT) or intravascular ultrasound (IVUS) — may be used to confirm stent apposition and expansion.
  7. Post-dilation — A non-compliant balloon may be used at high pressure to optimize stent expansion and minimize edge dissection.
  8. Final angiography — Confirms vessel patency, absence of dissection, and TIMI flow grade (typically TIMI 3, indicating complete perfusion).

Anticoagulation during the procedure — most commonly unfractionated heparin (UFH) or bivalirudin — is required to prevent catheter-related thrombosis. The specific agent and dosing are guided by activated clotting time (ACT) monitoring per institutional protocols aligned with Society for Cardiovascular Angiography and Interventions (SCAI) standards.

Common Scenarios

PCI is applied across a wide spectrum of clinical presentations, each carrying distinct urgency levels and procedural considerations:

Decision Boundaries

Choosing between PCI, coronary artery bypass grafting (CABG), and continued medications for heart disease requires systematic anatomical and clinical scoring. The 2021 ACC/AHA/SCAI Coronary Revascularization Guidelines formalize this process around two principal scoring systems:

Key anatomical contraindications to PCI include:

Procedural risk is categorized by SCAI shock classification (Stages A–E) for acute presentations and by the Society of Thoracic Surgeons (STS) risk model for elective cases being compared to CABG. Patients deemed too high risk for both PCI and CABG may be directed toward transcatheter aortic valve replacement pathways if valvular disease co-exists, or to LVAD and heart transplant evaluation in end-stage presentations.

Post-procedure, patients undergoing cardiac rehabilitation following PCI show measurable improvements in exercise tolerance and cardiovascular risk factor control, making structured rehabilitation an integral component of the procedural episode rather than an optional add-on.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)